Recent Progress of Palbociclib in Treatment of HR+/HER2- Breast Cancer
10.3971/j.issn.1000-8578.2022.22.0220
- VernacularTitle:哌柏西利治疗HR+/HER2-乳腺癌新进展
- Author:
Fangchao ZHENG
1
;
Feng DU
;
Haolin LIU
;
Xue WANG
;
Jian YUE
;
Peng YUAN
Author Information
1. Department of VIP Medical, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Publication Type:Research Article
- Keywords:
Palbociclib;
Breast cancer;
Cyclin-dependent kinases 4/6;
Hormone-receptor
- From:
Cancer Research on Prevention and Treatment
2022;49(7):703-708
- CountryChina
- Language:Chinese
-
Abstract:
As the first cyclin-dependent kinases 4 and 6 inhibitors, palbociclib significantly improved the survival of the patients with the hormone receptor-positive and human epidermal growth factor receptor-2 negative breast cancer. Palbociclib is a crucial landmark in the development history of antineoplastic drugs. This article reviews the mechanism of palbociclib, and summarizes the clinical trials, side effects, and the application of palbociclib.
